A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma.

Autor:	Mosquera Orgueira A; University Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, Spain.; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain., Díaz Arías JÁ; University Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, Spain.; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain., Serrano Martín R; University Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, Spain.; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain., Portela Piñeiro V; University Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, Spain.; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain., Cid López M; University Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, Spain.; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain., Peleteiro Raíndo A; University Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, Spain.; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain., Bao Pérez L; University Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, Spain.; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain., González Pérez MS; University Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, Spain.; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain., Pérez Encinas MM; University Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, Spain.; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain., Fraga Rodríguez MF; University Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, Spain.; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain., Vallejo Llamas JC; University Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, Spain.; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain., Bello López JL; University Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, Spain.; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2023 Apr 28; Vol. 13, pp. 1157646. Date of Electronic Publication: 2023 Apr 28 (Print Publication: 2023).
DOI:	10.3389/fonc.2023.1157646
Abstrakt:	Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of aggressive lymphoma. Approximately 60% of fit patients achieve curation with immunochemotherapy, but the remaining patients relapse or have refractory disease, which predicts a short survival. Traditionally, risk stratification in DLBCL has been based on scores that combine clinical variables. Other methodologies have been developed based on the identification of novel molecular features, such as mutational profiles and gene expression signatures. Recently, we developed the LymForest-25 profile, which provides a personalized survival risk prediction based on the integration of transcriptomic and clinical features using an artificial intelligence system. In the present report, we studied the relationship between the molecular variables included in LymForest-25 in the context of the data released by the REMoDL-B trial, which evaluated the addition of bortezomib to the standard treatment (R-CHOP) in the upfront setting of DLBCL. For this, we retrained the machine learning model of survival on the group of patients treated with R-CHOP (N=469) and then made survival predictions for those patients treated with bortezomib plus R-CHOP (N=459). According to these results, the RB-CHOP scheme achieved a 30% reduction in the risk of progression or death for the 50% of DLBCL patients at higher molecular risk (p-value 0.03), potentially expanding the effectiveness of this treatment to a wider patient population as compared with other previously defined risk groups. Competing Interests: AMO reports honoraria for lectures and participation in advisory boards from Janssen, Takeda, Abbey, Amgen, Novartis, Gilead and AstraZeneca; research grants from Roche, Pfizer and Celgene-BMS and funds for conference organization from Jassen, Takeda, Abbey, Amgen, Novartis, Gilead, Roche, Bristol-Myers-Squibb, Glaxo-Smith-Klyne, Incyte and Pfizer. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest. (Copyright © 2023 Mosquera Orgueira, Díaz Arías, Serrano Martín, Portela Piñeiro, Cid López, Peleteiro Raíndo, Bao Pérez, González Pérez, Pérez Encinas, Fraga Rodríguez, Vallejo Llamas and Bello López.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu